Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
ON-013100 is a novel and potent inhibitor of cell cycle with the potential for the treatment of mantle cell lymphoma. Briciclib, also referred to as ON 013105 or ON 014185, is the prodrug of ON-013100 that is a disodium phosphate ester and is an orally bioavailable small molecule that has better water solubility than ON 013100. It is a derivative of benzyl styryl sulfone, which may have anticancer properties and suppress the build-up of cyclin D1 in cancer cells. Briciclib binds to eIF4E, preventing the cap-dependent translation of cyclin D1 and other cancer proteins (c-MYC, VEGF), which results in the death of tumor cells, according to in vitro data. In nonclinical tumor models, briciclib has demonstrated potency and activity when paired with multiple chemotherapeutics. In conclusion, data from both in vitro and in vivo studies show that briciclib has the potential to target eIF4E in solid and hematopoietic cancers, and that an oral form of this exciting therapeutic agent may be developed.
Targets |
Cdk4/cyclin D1
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
|
Molecular Formula |
C19H22O7S
|
|
---|---|---|
Molecular Weight |
394.44
|
|
Exact Mass |
394.11
|
|
Elemental Analysis |
C, 57.86; H, 5.62; O, 28.39; S, 8.13
|
|
CAS # |
865783-95-5
|
|
Related CAS # |
Briciclib;865783-99-9
|
|
Appearance |
Solid powder
|
|
SMILES |
COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)O
|
|
InChi Key |
GHPUSRLWNSTQIK-BQYQJAHWSA-N
|
|
InChi Code |
InChI=1S/C19H22O7S/c1-23-14-10-18(25-3)15(19(11-14)26-4)7-8-27(21,22)12-13-5-6-17(24-2)16(20)9-13/h5-11,20H,12H2,1-4H3/b8-7+
|
|
Chemical Name |
2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]phenol
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 1.25 mg/mL (3.17 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (3.17 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5352 mL | 12.6762 mL | 25.3524 mL | |
5 mM | 0.5070 mL | 2.5352 mL | 5.0705 mL | |
10 mM | 0.2535 mL | 1.2676 mL | 2.5352 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Formulas of A: ON 013100, (E)-2,4,6-trimethoxystyryl-3-hydroxy-4-methoxybenzyl sulfone, C19H22O7S, 394.4 Da; B: Glucuronide of ON 013100, (E)-3,4,5-trihydroxy-6-{2-methoxy-5-[2-(2,4,6-trimethoxyphenyl)-ethenesulfonylmethyl]-phenoxy}-tetrahydropyran-2-carboxylic acid (570.5 Da); C: Structural analog of ON 013100, (E)-2,4,6-trimethoxystyryl-4-methoxybenzyl sulfone (378.5 Da), used as the internal standard (IS). J Pharm Biomed Anal . 2013 Mar 5:75:138-44. td> |
Synthetic scheme for glucuronide metabolite of (E)-2, 4, 6-Trimethoxystyryl-3-hydroxy-4-methoxybenzylsulfone (4) from ON 013100 (1) via compound (3). J Pharm Biomed Anal . 2013 Mar 5:75:138-44. td> |
Extracted ion chromatogram at m/z 571. Pellet sample from Colo-205 cells incubated with ON 013100 (20 µg/ml) for 1 h. J Pharm Biomed Anal . 2013 Mar 5:75:138-44. td> |